SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    NCCCR. North Carolina Facts and Figures. Atlanta, Georgia: American Cancer Society; 2004.
  • 2
    Medicine Io. The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington, DC: National Academies Press; 1999.
  • 3
    Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343: 7885.
  • 4
    Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997; 94: 33203323.
  • 5
    Hayes RB, Ziegler RG, Gridley G, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev. 1999; 8: 2534.
  • 6
    Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995; 274: 12771281.
  • 7
    Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999; 341: 11981205.
  • 8
    Field TS, Buist DS, Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005: 8895.
  • 9
    Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995; 13: 93100.
  • 10
    Institute of Medicine. The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington DC: National Academies Press; 1999.
  • 11
    Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001; 39: 11181130.
  • 12
    Stewart A WJ. Measuring functioning and well being: the medical outcomes study approach. Durham, NC: Duke University Press; 1992.
  • 13
    Safran DG, Kosinski M, Tarlov AR, et al. The Primary Care Assessment Survey: tests of data quality and measurement performance. Med Care. 1998; 36: 728739.
  • 14
    Sherbourne CD, Stewart AL. The MOS Social Support Survey. Soc Sci Med. 1991; 32: 705714.
  • 15
    MacDonald LD, Anderson HR. Stigma in patients with rectal cancer: a community study. J Epidemiol Community Health. 1984; 38: 284290.
  • 16
    SAS [computer program]. Cary, NC: SAS Institute; 2003.
  • 17
    Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans' willingness to participate in medical research studies. Cancer. 2001; 91(1 Suppl ): 233236.
  • 18
    Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc. 1996; 88: 630634.
  • 19
    Shavers VL, Lynch CF, Burmeister LF. Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol. 2002; 12: 248256.
  • 20
    Freedman TG. “Why don't they come to Pike Street and ask us”?: Black American women's health concerns. Soc Sci Med. 1998; 47: 941947.
  • 21
    Powell ME, Carter V, Bonsi E, et al. Increasing mammography screening among African American women in rural areas. J Health Care Poor Underserved. 2005; 16(4 Suppl A ): 1121.
  • 22
    Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002; 347: 15851592.
  • 23
    Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005; 294: 17651772.
  • 24
    Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996; 34: 152162.
  • 25
    Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998; 36: 13371348.
  • 26
    Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004; 64: 11711176.
  • 27
    Cohen JH, Schenck AP, Kaufman JS, et al. Racial differences in disease-free survival in a Medicare population after treatment for clinically localized prostate cancer. Cancer Causes Control. 2006; 17: 803811.
  • 28
    Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003; 95: 17021710.
  • 29
    Finney Rutten LJ, Meissner HI, Breen N, Vernon SW, Rimer BK. Factors associated with men's use of prostate-specific antigen screening: evidence from Health Information National Trends Survey. Prev Med. 2005; 40: 461468.
  • 30
    Han PK, Coates RJ, Uhler RJ, Breen N. Decision making in prostate-specific antigen screening National Health Interview Survey, 2000. Am J Prev Med. 2006; 30: 394404.
  • 31
    Federman DG, Goyal S, Kamina A, Peduzzi P, Concato J. Informed consent for PSA screening: does it happen? Eff Clin Pract. 1999; 2: 152157.
  • 32
    Volk RJ, Cass AR. The accuracy of primary care patients' self-reports of prostate-specific antigen testing. Am J Prev Med. 2002; 22: 5658.
  • 33
    Black WC, Nease RFJr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995; 87: 720731.